Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc

Bullboard Posts

Post by JLGeminion May 11, 2011 9:03am

215 Views

Post# 18558704

Rounding the Far Post - Hold and Buy Oncolytics

Today’s AGM will be different than prior ones. This morning’s timed announcement of the supply agreement is another indication that the commercialization of Reolysin is rounding the corner to the home stretch. AMGN paid $1 billion for Biovex. The market cap of ONC is under $390 million. The days of the buy side manipulation are coming to an end and the shorts have limited time to cover their bets. Hold and buy Oncolytics. How many trading days until the World Lung Cancer Conference?

Bullboard Posts

Advancing flagship Ishkõday Gold Project in Ontario